Clinical Trial Update: Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating AVM0703 for ARDS associated with COVID-19 or influenza, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• AVM0703

Snippet

Sponsor: AVM Biotechnology Inc | Conditions: ARDS, Covid19 | Phase 1 | Status: NOT_YET_RECRUITING